MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $1.16 Million Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 3.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 20,926 shares of the company’s stock after purchasing an additional 724 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.05% of Tarsus Pharmaceuticals worth $1,159,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Janus Henderson Group PLC increased its position in shares of Tarsus Pharmaceuticals by 47.2% in the fourth quarter. Janus Henderson Group PLC now owns 12,482 shares of the company’s stock worth $691,000 after acquiring an additional 4,000 shares in the last quarter. Deutsche Bank AG boosted its stake in Tarsus Pharmaceuticals by 93.8% in the 4th quarter. Deutsche Bank AG now owns 153,441 shares of the company’s stock worth $8,496,000 after purchasing an additional 74,275 shares during the period. D. E. Shaw & Co. Inc. grew its position in Tarsus Pharmaceuticals by 100.7% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 365,544 shares of the company’s stock worth $20,240,000 after purchasing an additional 183,449 shares in the last quarter. Corton Capital Inc. purchased a new position in Tarsus Pharmaceuticals during the 4th quarter worth approximately $261,000. Finally, Cutter Capital Management LP acquired a new stake in Tarsus Pharmaceuticals during the 4th quarter valued at $6,229,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Insiders Place Their Bets

In other news, General Counsel Bryan Wahl sold 3,084 shares of the company’s stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $50.11, for a total transaction of $154,539.24. Following the completion of the sale, the general counsel now owns 51,712 shares in the company, valued at approximately $2,591,288.32. This represents a 5.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Dianne C. Whitfield sold 2,315 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $107,161.35. Following the completion of the transaction, the insider now directly owns 50,751 shares in the company, valued at $2,349,263.79. The trade was a 4.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 32,542 shares of company stock valued at $1,581,173 over the last three months. 8.25% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Wall Street Zen downgraded Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday. Guggenheim lifted their target price on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a “buy” rating in a research note on Friday, May 2nd. Barclays reduced their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. HC Wainwright restated a “buy” rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Finally, Jefferies Financial Group upped their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $66.33.

Tarsus Pharmaceuticals Trading Up 0.0%

NASDAQ:TARS opened at $42.98 on Monday. The company has a market capitalization of $1.81 billion, a P/E ratio of -11.28 and a beta of 0.94. The stock’s 50 day moving average price is $47.73 and its 200 day moving average price is $49.14. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals, Inc. has a 52 week low of $20.08 and a 52 week high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.05. The company had revenue of $78.34 million for the quarter, compared to analyst estimates of $72.50 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. On average, research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.